One such previous study indicated possible cardiac benefits (possibly mediated through GLP-1) and showed that DPP-4 inhibitors may also have direct effects on the heart and on cardiovascular risk factors (such as hypertension and hyperlipidaemia), independent of the incretin system (Zhang et al., 2019). The gene discussed is GCG; the disease is hypertensive disorder.